Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2407
Título : Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Autor : Neukam, Karin
Munteanu, Daniela I
Rivero-Juárez, Antonio
Lutz, Thomas
Fehr, Jan
Mandorfer, Mattias
Bhagani, Sanjay
López-Cortés, Luis F
Haberl, Annette
Stoeckle, Marcel
Márquez, Manuel
Scholten, Stefan
de Los Santos-Gil, Ignacio
Mauss, Stefan
Rivero, Antonio
Collado, Antonio
Delgado, Marcial
Rockstroh, Juergen K
Pineda, Juan A
Filiación: [Neukam,K; Pineda,Ja] Unit of Infectious Diseases and Microbiology, Valme University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain. [Neukam,K; Rivero-Juárez,A; López-Cortés,LF; Márquez,M; de los Santos-Gil,I; Rivero,A; Pineda,JA] RIS-HEP07 Study Group of the Spanish AIDS Research Network. [Munteanu,DI; Rockstroh,JK] Department of Medicine I, Bonn University Hospital, Bonn-Venusberg, Germany. [Munteanu,DI] Matei Bals National Institute of Infectious Diseases, Bucharest, Romania. [Rivero-Juárez,A; Rivero,A] Unit of Infectious Diseases, Reina Sofía University Hospital, Maimónides Institute of Biomedical Investigation of Cordoba (IMIBIC), Cordoba, Spain. [Lutz,T] Infektiologikum Frankfurt, Frankfurt/Main, Germany. [Fehr,J] Division of Infectious Diseases & Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. [Mandorfer,M] Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna and Vienna HIV & Liver Study Group, Vienna, Austria. [Bhagani,S] Department of Infectious Diseases/HIV Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom. [López-Cortés,LF] Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain. [Haberl,A] Department of Medicine II, Frankfurt University Hospital, Frankfurt/Main, Germany. [Stoeckle,M] Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. [Márquez,M] Unit of Infectious Diseases, Virgen de la Victoria University Hospital, Malaga, Spain. [Scholten,S] Praxis Hohenstaufenring, Cologne, Germany. [de los Santos-Gil, I] Infectious Diseases Unit, La Princesa University Hospital, Madrid, Spain. [Mauss,S] Center for HIV and Hepatogastroenterology, Dusseldorf, Germany. [Collado,A] Infectious Diseases Unit, Torrecardenas University Hospital, Almeria, Spain. [Delgado,M] Unit of Infectious Diseases, Carlos Haya Regional University Hospital, Malaga, Spain.
Palabras clave : Coinfección
Europa
Femenino
VIH
Adulto
Hepacivirus
Infecciones por VIH
Hepatitis C crónica
Humanos
Masculino
Mediana edad
Oligopéptidos
Prolina
Rivavirina
Resultado del tratamiento
MeSH: Medical Subject Headings::Diseases::Virus Diseases::Coinfection
Medical Subject Headings::Geographicals::Geographic Locations::Europe
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV
Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Medical Subject Headings::Organisms::Viruses::Hepatitis Viruses::Hepacivirus
Medical Subject Headings::Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Aged
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Oligopeptides
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Imino Acids::Proline
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::Ribavirin
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult
Fecha de publicación : 29-Apr-2015
Editorial : Public Libray of Science
Cita Bibliográfica: Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, et al. Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PLoS ONE. 2015; 10(4):e0125080
Abstract: BACKGROUND AND AIMS Clinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alone. This study sought to evaluate the efficacy and safety of triple therapy including BOC or TVR in combination with PR in HIV/HCV-coinfected patients under real-life conditions. METHODS In a multicentre study conducted in 24 sites throughout five European countries, all HIV/HCV-coinfected patients who initiated a combination of BOC or TVR plus PR and who had at least 60 weeks of follow-up, were analyzed. Sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) and the rate of discontinuations due to adverse events (AE) were evaluated. RESULTS Of the 159 subjects included, 127 (79.9%) were male, 45 (34.4%) were treatment-naïve for PR and 60 (45.4%) showed cirrhosis. SVR12 was observed in 31/46 (67.4%) patients treated with BOC and 69/113 (61.1%) patients treated with TVR. Overall discontinuations due to AE rates were 8.7% for BOC and 8% for TVR. Grade 3 or 4 hematological abnormalities were frequently observed; anemia 7%, thrombocytopenia 17.2% and neutropenia 16.4%. CONCLUSION The efficacy and safety of triple therapy including BOC or TVR plus PR under real-life conditions of use in the HIV/HCV-coinfected population was similar to what is observed in clinical trials. Hematological side effects are frequent but manageable.
Descripción : Journal Article; Research Support, Non-U.S. Gov't;
URI: http://hdl.handle.net/10668/2407
Versión del editor : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125080
DOI: 10.1371/journal.pone.0125080
ISSN : 1932-6203 (Online)
Appears in Collections:01- Artículos - Complejo Hospitalario Torrecárdenas
01- Artículos - Hospital Virgen de la Victoria
01- Artículos - Hospital Virgen del Rocío
01- Artículos - IMIBIC. Instituto Maimónides de Investigación Biomédica de Córdoba
01- Artículos - Hospital Reina Sofía
01- Artículos - IBIS. Instituto de Biomedicina de Sevilla
01- Artículos - AGS Sur de Sevilla
01- Artículos - Hospital Regional de Málaga

Files in This Item:
File Description SizeFormat 
NeukamK_BroceprevirOrTelaprevir.pdfArtículo publicado294,94 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons